[1]Miccoli P, Minuto MN, Ugolini C, et al. Papillary thyroid cancer: pathological parameters as prognostic factors in different classes of age[J]. Otolaryngol Head Neck Surg, 2008, 138(2): 200-203.
[2]Newman KD. The current management of thyroid tumors in childhood[J]. Semin Pediatr Surg, 1993, 2(1): 69-74.
[3]Steliarova-Foucher E, Stiller CA, Pukkala E, et al. Thyroid cancer incidence and survival among European children and adolescents (1978-1997): report from the Automated Childhood Cancer Information System project[J]. Eur J Cancer, 2006, 42(13): 2150-2169.
[4]Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades[J]. Surgery, 1988, 104(6): 1157-1166.
[5]Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid in-volvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients[J]. Cancer, 1992, 70(6): 1585-1590.
[6]Dinauer C, Francis GL. Thyroid cancer in children[J]. Endo-crinol Metab Clin North Am, 2007, 36(3): 779-806.
[7]Gharib H, Papini E.Thyroid nodules: clinical importance, assessment, and treatment[J]. Endocrinol Metab Clin North Am, 2007, 36(3): 707-735.
[8]Halac I, Zimmerman D. Thyroid nodules and cancers in children[J]. Endocrinol Metab Clin North Am, 2005, 34(3): 725-744.
[9]李会政, 唐平章, 徐震纲, 等. 青少年分化型甲状腺癌治疗及预后[J].中国耳鼻咽喉头颈外科, 2008, 15(1): 15-18.
[10]龚建平, 张仁希, 陈环球, 等. 青少年分化型甲状腺癌的临床特点及治疗选择[J].中华外科杂志, 2006, 44(21): 1483-1485.
[11]蔡永聪, 王朝晖, 陈建超, 等. 青少年甲状腺癌的临床分析[J]. 中华临床医师杂志, 2011, 5(10): 3056-3067.
[12]Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables[J]. Clin Oncol (R Coll Radiol), 2010, 22(6): 395-404.
[13]Agac Ay A, Kutun S, Cetin A. Are the characteristics of thy-roid cancer different in young patients?[J]. J Pediatr Endo-crinol Metab, 2014, 27(5-6): 497-502.
[14]Haymart MR. Understanding the relationship between age and thyroid cancer[J]. Oncologist, 2009, 14(3): 216-221.
[15]O’Gorman CS, Hamilton J, Rachmiel M, et al. Thyroid cancer in childhood: a retrospective review of childhood course[J]. Thyroid, 2010, 20(4): 375-380.
[16]Okada T, Sasaki F, Takahashi H, et al. Management of childhood and adolescent thyroid carcinoma: long-term follow-up and clinical characteristics[J]. Eur J Pediatr Surg, 2006, 16(1): 8-13.
[17]金国萍, 孟昭忠, 罗瑞华, 等. 86例青少年甲状腺癌的临床分析[J]. 中华肿瘤杂志, 2004, 26(1): 49-51.
[18]Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: determinants of disease progression in patients < 21 years of age at diagnosis: a report from the Surgical Disci-pline Committee of the Children’s Cancer Group[J]. Ann Surg, 1998, 227(4): 533-541.
[19]Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review[J]. Endocr Relat Cancer, 2005, 12(4): 773-803.
[20]荆凡静, 梁军, 赵丹, 等. 青少年与成人远处转移性甲状腺乳头状癌临床病理特征对比[J]. 中华肿瘤防治杂志, 2013, 20(8): 618-621.
[21]Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin[J]. Endocr Relat Cancer, 2002, 9(4): 227-247.
[22]Hogan AR, Zhuge Y, Perez EA, et al. Pediatric thyroid car-cinoma: incidence and outcomes in 1753 patients[J]. J Surg Res, 2009, 156(1): 167-172.
[23]Xing M. Genetic alterations in the phosphatidylinositol-3 ki-nase/Akt pathway in thyroid cancer[J]. Thyroid, 2010, 20(7): 697-706.
[24]Kogai T, Sajid-Crockett S, Newmarch LS, et al. Phos-phoinositide-3-kinase inhibition induces sodium/iodide sym-porter expression in rat thyroid cells and human papillary thyroid cancer cells[J]. J Endocrinol, 2008, 199(2): 243-252.
[25]Yamashita S, Saenko V. Mechanisms of disease: molecular genetics of childhood thyroid cancers[J]. Nat Clin Pract En-docrinol Metab, 2007, 3(5): 422-429.
[26]Diesen DL, Skinner MA. Pediatric thyroid cancer[J]. Semin Pediatr Surg, 2012, 21(1): 44-50.
[27]Liu D, Liu Z, Condouris S, et al. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells[J]. J Clin Endocrinol Metab, 2007, 92(6): 2264-2271.
[28]Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mu-tation and p27 kip1 expression in papillary carcinomas of the thyroid < or=1 cm and their paired lymph node metasta-ses[J]. Cancer, 2007, 110(6): 1218-1226.
[29]Poghosyan Z, Wynford-Thomas D. Analysis of Ras transformation of human thyroid epithelial cells[J]. Methods En-zymol, 2006, 407: 648-660.
[30]Collini P, Massimino M, Leite SF, et al. Papillary thyroid carcinoma of childhood and adolescence: a 30-year experience at the Istituto Nazionale Tumori in Milan[J]. Pediatr Blood Cancer, 2006, 46(3): 300-306.
[31]Ramirez R, Hsu D, Patel A, et al. Over-expression of hepa-tocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of me-tastasis and recurrence for children and young adults with papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2000, 53(5): 635-644.
